
Disclaimer: This course contains the use of artificial intelligence.
Launch Fast, Lose Billions: Master the Dark Art of Pharma Market Access
Every $1 of list price you announce triggers a global chain reaction. A €50,000 price in Italy becomes €8,000 in Brazil within 42 days. A rushed Alzheimer's launch cost one company $4.2 billion—95% of projected revenue. The problem? You're optimizing for speed while the market is optimizing for your failure.
This isn't a course about rebates and paperwork. It's a strategic weapons system for pricing leaders who refuse to let 40-60% of revenue vanish through PBM black boxes, 340B traps, and IRP cascades.
Across six integrated modules, you'll deconstruct real-world catastrophes (a $2.3B pricing disaster), reverse-engineer billion-dollar successes (GeneCure's $1.2M gene therapy MEA), and master the mathematical models that predict payer behavior with 80% accuracy.
What You'll Build:
IRP Propagation Models that map how a price change in Portugal ripples to 37 countries
Launch Sequencing Algorithms that calculate the exact 6-month stabilization window worth $180M
Gross-to-Net Defense Systems to claw back $20-40M annually from DIR fees and contract pharmacy leakage
Outcome-Based MEA Contracts that turn "your drug is too expensive" into "we'll pay $100K if it works"
The capstone simulation throws you into the hot seat: Navigate a Korean competitor ambush, choreograph a 5-market launch, and see your decisions hit real-time P&L. Score yourself against the $418M optimal blueprint.
If you're done leaving billions on the table, this is your playbook.